Innovent, Roche partner on cell therapies, bispecific antibodies

By The Science Advisory Board staff writers

June 9, 2020 -- Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.

The collaboration will focus on the discovery, clinical development, and commercialization of bispecific antibodies (antibodies that simultaneously bind separate and unique antigens) and multiple cell therapies. These therapies will be targeted for the treatment of hematological and solid cancers.

Under the agreement, Innovent will pay development and commercial milestone payments and royalties upfront to nonexclusively access certain Roche technologies that enable the discovery and development of 2:1 T-cell bispecific antibodies and a universal chimeric antigen receptor-T (CAR-T) cell platform.

Innovent will create, develop, manufacture, and commercialize the products. Roche retains the right to license each product for development outside of China.

Ligand, Roche to develop ion channel drug discovery platform
Ligand Pharmaceuticals and Icagen have expanded Icagen's license agreement with Roche to develop and commercialize small molecule ion channel modulators...
Vividion, Roche partner for small-molecule drug discovery
Biotechnology company Vividion Therapeutics has signed an exclusive worldwide option and license agreement with Roche.
Roche becomes founding partner of biotech accelerator
Roche has become a founding partner in the second phase of development of BaseLaunch, a Basel, Switzerland-based incubator and accelerator that helps...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter